We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Metabolic Biomarker Panel Shows Promise for Diagnosis of Dementia

By LabMedica International staff writers
Posted on 22 Sep 2021
Print article
A heat-map, where red shows high levels of a compound, and blue shows low levels of a compounds, reveals the link between certain metabolites and dementia. Compounds in sub-group A were typically higher in dementia patients and lower in healthy elderly people. Compounds in sub-group B-E showed the opposite effect (Photo courtesy of Okinawa Institute of Science and Technology)
A heat-map, where red shows high levels of a compound, and blue shows low levels of a compounds, reveals the link between certain metabolites and dementia. Compounds in sub-group A were typically higher in dementia patients and lower in healthy elderly people. Compounds in sub-group B-E showed the opposite effect (Photo courtesy of Okinawa Institute of Science and Technology)
A biomarker panel based on five groups of metabolites was shown to be potentially useful for diagnosis and therapy of various forms of dementia, such as Alzheimer’s disease.

Dementia, which is caused by factors that damage neurons, is characterized by a slowly progressing, chronic, and usually irreversible decline in cognitive function. The exact cause of neuron damage, and methods for its detection and treatment have remained elusive.

To rectify this situation, investigators at the Okinawa Institute of Science and Technology (Japan) employed nontargeted liquid chromatography–mass spectroscopy (LC-MS) to quantify small molecular markers in whole blood samples taken from of dementia patients. For this study, the investigators exhaustively analyzed blood samples collected from eight patients with dementia, from eight healthy elderly individuals, and from eight healthy young individuals. Overall, the investigators measured the levels of 124 different metabolites for each patient.

Analysis of the results revealed that 33 metabolites, classified into five groups (A to E), differed significantly in dementia patients, compared with healthy elderly subjects. Seven Group A metabolites present in plasma, including quinolinic acid, kynurenine, and indoxyl-sulfate, increased. The investigators suggested that these compounds may act as neurotoxins, damaging the central nervous system.

The remaining 26 compounds (in groups B to E) decreased in dementia patients, possibly causing a loss of support or protection of the brain in dementia. These compounds were thought to protect the nervous system against oxidative stress, maintain energy reserves, supply nutrients and act as neuroprotective factors.

“Identification of these compounds means that we are one step closer to being able to molecularly diagnose dementia,” said senior author Dr. Mitsuhiro Yanagida, head of the G0 Cell Unit at the Okinawa Institute of Science and Technology. “It is still too early to say, but it could suggest a possible mechanistic cause of dementia as these compounds may lead to impairment of the brain. In the future, we hope to start some intervention studies, either by supplementing dementia patients with metabolic compounds in sub-groups B-E, or by inhibiting the neurotoxins from sub-group A, to see if that can slow, prevent, or even reverse symptoms of dementia.”

The dementia study was published in the September 14, 2021, online edition of the journal Proceedings of the National Academy of Sciences of the United States of America.

Related Links:

Okinawa Institute of Science and Technology

Gold Supplier
Real-Time PCR System
CFX Opus 384 System
New
Cardiovascular Disease POC Analyzer
cobas h 232 POC System
New
Lateral Flow Test Cassette Reader
Quantum Blue III
New
Bulk Sorter
BL 1200 SORT CONNECT

Print article

Channels

Hematology

view channel
Image: The Gazelle Hb Variant Test for screening, diagnosis and management of sickle cell disease and related hemoglobinopathies at the point of care (Photo courtesy of Hemex Health)

Point-of-Care Device Accurately Rapidly Diagnoses Sickle Cell Disease

Hemoglobinopathies are the most common autosomal hereditary disorders. Approximately 7% of the global population carries hemoglobin gene mutation including structural hemoglobin variants like sickle hemoglobin... Read more

Immunology

view channel
Image: The IMMULITE 2000 XPi Immunoassay System provides multiple tests on a single, easy-to-use analyzer, including the thyroid-stimulating immunoglobulin assay (Photo courtesy of Siemens Healthcare)

Immunoassays Evaluated for Thyroid-Stimulating Receptor Antibody in Graves’ Disease

Graves' disease (GD), also known as toxic diffuse goiter, is an autoimmune disease that affects the thyroid. It frequently results in and is the most common cause of hyperthyroidism and it also often results... Read more

Microbiology

view channel
Image: The sciREADER CL2 enables high quality digital colorimetric imaging of various support formats (Photo courtesy of SCIENION)

Multiplex Immunoassay Developed for Confirmation and Typing of HTLV Infections

Human T-Cell Lymphotropic Viruses (HTLV) type 1 and type 2 account for an estimated five to 10 million infections worldwide and are transmitted through breast feeding, sexual contacts and contaminated... Read more

Pathology

view channel
Illustration

AI Accurately Detects and Diagnoses Colorectal Cancer from Tissue Scans As Well or Better Than Pathologists

Artificial intelligence (A) can accurately detect and diagnose colorectal cancer from tissue scans as well or better than pathologists, according to a new study. The study, which was conducted by researchers... Read more

Technology

view channel
Image: PKeye Workflow Monitor System (Photo courtesy of PerkinElmer, Inc.)

PerkinElmer’s New Cloud-Based Platform Enables Laboratory Personnel to Remotely Manage Its Instruments in Real-Time

PerkinElmer, Inc. (Waltham, MA; USA) has launched its PKeye Workflow Monitor, a cloud-based platform enabling laboratory personnel to remotely manage and monitor their PerkinElmer instruments and workflows... Read more

Industry

view channel
Illustration

Global Point of Care Diagnostics Market to Top USD 35 Billion by 2027 Due to Rising Diabetic Cases

The global point of care diagnostics market is projected to grow at a CAGR of close to 6% from more than USD 23 billion in 2020 to over USD 35 billion by 2027, driven by an increase in the number of diabetic... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.